Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q2 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $47.4 million versus the consensus estimate of $44.82 million.

Meridian Bioscience, Inc. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.

Earnings Guidance